JNK

Loureirin B suppresses fibrosis by modulating MMPs/TIMPs, hindering fibroblast growth, and targeting TGF-β1/Smad2/3 pathway.

Tomatidine hydrochloride (Tomatidine HCl) is a steriodal alkaloid structurally similar to Cyclopamine but does not inhibit hedgehog pathway.

Actein stimulates bone formation, counters osteoporosis and oxidative damage, and may treat lipid disorders and cancer, inhibiting breast cancer cell growth.

Polyphyllin D induces apoptosis via the mitochondrial apoptotic pathway as evidenced by decreased Bcl-2 expression levels, disruption of MMP and increased Bax,

Ro 31-8220 Mesylate (Bisindolylmaleimide IX mesylate) is a pan-PKC inhibitor, and also shows potent inhibition against MSK1, MAPKAP-K1b, S6K1, and GSK3β.

Guggulsterone (Guggulsterone E&Z) E&Z is a 3-hydroxy steroid. It has a role as an androgen.

JNK-IN-7 (JNK inhibitor) is a selective JNK1/2/3 inhibitor (IC50: 1.54/1.99/0.75 nM).

CC-401 Hydrochloride (CC401 HCl) is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with antineoplastic activity.

JNK peptide inhibitor. Mimics JIP-1 residues 153-163. Micromolar affinity, little effect on p38, ERK.

Ro 31-8220: potent PKC inhibitor (IC50: 5-27 nM). Affects MAPKAP-K1b, MSK1, S6K1, GSK3β (IC50: 3-38 nM), not MKK3/4/6/7.

Bentamapimod (AS 602801) is a novel, orally active inhibitor of JNK.

Astragaloside IV suppresses ERK1/2, JNK, MMP-2/9 in breast cancer; inhibits adenovirus and protects cardiovascular, immune, digestive, nervous systems.

JNK-IN-8 (JNK Inhibitor XVI) is an irreversible JNK1/2/4 inhibitor (IC50: 4.7/18.7/1 nM).

Epieriocalyxin A can suppress Caco-2 colon cancer cell growth. It could be a potential drug for colon cancer therapy in the future.

Juglanin is a JNK activator. Juglanin with inflammation and anti-tumor activities. It can induce apoptosis and autophagy on human breast cancer cells.

TRi-1 irreversibly inhibits TXNRD1 (IC50: 12 nM) with low mitochondrial toxicity for cancer treatment.

1.

Indirubin-3′-oxime is an effective inhibitor of cyclin-dependent protein kinases, and may play an obligate role in neuronal apoptosis in Alzheimer's disease.

IQ-1S free acid (IQ-1S) is an effective and specific c-Jun N-Terminal Kinase Inhibitor. IQ-1S inhibits murine delayed-type hypersensitivity.

Sodium taurochenodeoxycholate: induces apoptosis, anti-inflammatory, boosts insulin, stimulates α2-cells, increases [Ca(2+)](c).

Fasudil hydrochloride (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.

CC-90001 is an orally administered c-Jun N-terminal kinase (JNK) inhibitor with bias for JNK1 over JNK2.

Phytolaccaceae has anti-tumor activity, the mechanism may be related to the capacity of Esculentoside H for TNF release.

TCS JNK 5a (SC202671) is an effective, specific inhibitor of JNK3(pIC50= 6.7), JNK2(pIC50=6.5).

Ginsenoside Re (Ginsenoside B2) may have properties that inhibit or prevent the growth of tumors.

WHI-P258, a weak JAK3 inhibitor, is used as a negative control in drug development.

Sesamolin and sesamin guard nerves, reduce microglia damage by blocking p38 MAPK and caspase-3, and curb nitric oxide in stimulated cells.

Pamapimod (R1503) (R-1503, Ro4402257) is a novel, selective inhibitor of p38 mitogen-activated protein kinase.

SR-3306 is a brain-penetrant and selective pan-JNK (JNK1/2/3) inhibitor with IC50 values ​​of 67 nM, 283 nM, 159 nM.Cost-effective and quality-assured.

SR-3737 is potent both JNK3 and p38 inhibitor.

TOPK-p38/JNK-IN-1 (Compound B12) is an orally active inhibitor of the TOPK-p38/JNK signaling pathway, with an IC50 value of 2.14 μM for the inhibition of NO

BSJ-04-122: MKK4/7 inhibitor with IC50s of 4 nM & 181 nM, used in cancer research.

SX 011 is a p38α inhibitor.

GSK649A is a novel activator of Satellite Cell Proliferation, it could enhance repair of Damaged Muscle.

J30-8 is a JNK3 inhibitor (IC50: 40 nM) with neuroprotective activity and can be used to study neurodegenerative diseases such as Alzheimer's disease.

ZG-10 (JNK-IN-2) is an inhibitor of JNK, blocking JNK1, JNK2, and JNK3, and is used in studies of SARS-CoV-2 virus infection.

JNK3 inhibitor, potent and selective

JNK-1-IN-1 is an inhibitor specifically targeting JNK-1, also exhibiting inhibition of MKK7 with an IC50 value of 7.8μM.

JNK-IN-11 inhibits JNK1/2/3 (IC50: 2.2/21.4/1.8 μM); promising for Alzheimer's/Parkinson's research.

TC ASK 10 is a potent, selective and orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1,IC50 = 14 nM). The IC50 value for ASK2 is 0.51 μM.

JNK3 Inhibitor-3 selectively blocks JNK3 (>4.1 nM), crosses the blood-brain barrier, is orally active, and improves memory in dementia mice.

JNK3 inhibitor-1: potent, selective, IC50 of 0.005 μM, orally bioavailable, brain-penetrant.

Ezatiostat HCl (TLK199) inhibits glutathione S-transferase, GSTP1-1 specifically, and may treat cytopenias.

JNK-1-IN-4 (Compound E1) is an inhibitor of JNK, targeting JNK-1, JNK-2, and JNK-3 with IC50 values of 2.7, 19.0, and 9.0 nM, respectively. This compound inhibits the phosphorylation of c-Jun and reduces the expression of TGF-β1-induced EMT markers (such as fibronectin and α-SMA). JNK-1-IN-4 exhibits favorable pharmacokinetic properties with a bioavailability of 69%. Additionally, it demonstrates antifibrotic effects in a Bleomycin-induced mouse model of idiopathic pulmonary fibrosis.

p38 Kinase inhibitor 8 (Compound CCLXXVIII) is an orally active inhibitor targeting p38β and JNK2α2, with IC50 values of 6.3 nM and 53.6 nM, respectively. It has demonstrated anti-inflammatory effects in a rat model of collagen-induced arthritis.

JNK-IN-21 (Compound 62) is an inhibitor of JNK-1.

PT109 is a multikinase inhibitor that targets JNK and other kinases, playing a crucial role in anti-inflammatory, antioxidative, neurogenic, and synaptogenic processes. Specifically, PT109 inhibits JNK isoforms with the following IC50 values: JNK1 at 0.143 μM, JNK2 at 0.831 μM, and JNK3 at 0.285 μM. It also inhibits SGK isoforms (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM) and ROCK2 (IC50=34 μM). Additionally, PT109 reprograms polymorphic glioblastoma multiforme (GBM) into oligodendroglia via the PTBP1/PKM1/2 pathway and alters the metabolic pattern of GBM to exhibit antiglioma activity.